R&D Strategies at Pharmaceutical Companies 2020

Language:
Japanese
Product Code No:
C61124200
Issued In:
2020/03
#of Pages:
275
Publication Cycle:
  
Format:
PDF

Price

130,000 yen ($1,191.02)
(excluding consumption tax)
260,000 yen ($2,382.04)
(excluding consumption tax)
390,000 yen ($3,573.06)
(excluding consumption tax)
* Equivalent value in US$ (Today's rate : $1= 109.15 yen , 2020/04/07 Japan)

Coverage: (Product/service)

R&D Strategies at Pharmaceutical Companies

Research Target:

Pharmaceutical Companies

Research Content:

I   Overview

1. R&D Strategies at Pharmaceutical Companies
2. CRO Market Status 
3. SMO Market Status 

II   R&D Strategies at Leading Pharmaceutical Enterprises

1. Astellas Pharma Inc.
2. AstraZeneca K.K.
3. Eisai Co., Ltd.
4. MSD K.K. a subsidiary of Merck & Co., Inc.,
5. Otsuka Holdings Co., Ltd.
6. ONO PHARMACEUTICAL CO., LTD.
7. Kyowa Hakko Kirin Co., Ltd.
8. GlaxoSmithKline K.K.
9. Sanofi K.K.
10. SHIONOGI & CO., LTD.
11. DAIICHI SANKYO COMPANY, LIMITED
12. Sumitomo Dainippon Pharma Co., Ltd.
13. Takeda Pharmaceutical Company Limited.
14. Mitsubishi Tanabe Pharma Corporation
15. CHUGAI PHARMACEUTICAL CO., LTD.
16. Eli Lilly Japan K.K.
17. Boehringer Ingelheim Japan, Inc.
18. Novartis Pharma K.K.
19. Bayer Yakuhin, Ltd.
20. Pfizer Japn, Inc.

III   Strategies of CRO/SMO Enterprises

1. EPS Holdings, Inc. 
2. A2 Healthcare Corp.
3. M3, Inc.)
4. CMIC HOLDINGS Co., Ltd..
5. Micron Inc.
• Leading CRO Enterprises: 30 enterprises,
• Leading SMO Enterprises: 28 enterprises

Price

written in Japanese
130,000 yen ($1,191.02)
(excluding consumption tax)
260,000 yen ($2,382.04)
(excluding consumption tax)
390,000 yen ($3,573.06)
(excluding consumption tax)
* Equivalent value in US$ (Today's rate : $1= 109.15 yen , 2020/04/07 Japan)